Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
OBJECTIVE
To determine the nature and degree of toxicity, response rate, quality of life (QOL), and progression-free interval in women with platinum-resistant refractory ovarian or peritoneal cancer receiving weekly topotecan and gemcitabine.


METHODS
A Phase II trial of gemcitabine 800 mg/m(2) and topotecan 3.0 or 2.5 mg/m(2) administered on days 1 and 8 of a 21-day cycle was conducted. Response was assessed by RECIST criteria. Quality of life was assessed with FACT-O.


RESULTS
Twenty-three patients were enrolled in the study and all were evaluable. One patient was later found to be ineligible due to a concurrent endometrial malignancy, but remains part of the analysis. Sixteen patients (70%) had measurable disease at baseline and 7 (30%) had elevated CA125 only. The median number of prior regimens was 1, range 1-4 and median number of prior cycles was 8, range 3-39. The first 6 patients received topotecan at a dose of 3.0 mg/m(2), but because of dose delays and need for GCSF the dose of topotecan was lowered to 2.5 mg/m(2). There were 4 (17%) partial responses, but only two (9%) were confirmed prior to progression; and 8 (35%) had stable disease. Toxicity was acceptable with only 8 of the 107 cycles given requiring a dose reduction. Four patients (17%) were taken off the study for toxicity, two at the higher dose and two at the lower dose. Median time to recurrence was 3.0 months and median overall survival was 12.6 months. QOL did not differ with subsequent cycles as compared to baseline.


CONCLUSIONS
The combination of weekly topotecan and gemcitabine is well tolerated, but best response rate is 17%, and confirmed response is only 9%, which is not significantly better than single agent gemcitabine or topotecan. These results do not provide compelling evidence for the combination of weekly gemcitabine and topotecan as a promising therapy.
Goff
Barbara A
BA
Department of Obstetrics and Gynecology, University of Washington School of Medicine, Seattle WA 98195, USA. bgoff@u.washington.edu
Holmberg
Leona A
LA
Veljovich
Dan
D
Kurland
Brenda F
BF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
D003841:Deoxycytidine; D016179:Granulocyte Colony-Stimulating Factor; D019772:Topotecan; D000093542:Gemcitabine